Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (NASDAQ: TWST) is a synthetic biology and biotechnology company whose news flow reflects its focus on synthetic DNA tools, silicon-based DNA synthesis and research-enabling technologies. Company announcements frequently describe Twist as a mid-cap growth and value biotech company serving customers in medicine, agriculture, industrial chemicals and defense, where its DNA-based products support research and development programs.
On this page, readers can follow TWST news related to product launches, collaborations, financial updates and corporate developments. Recent press releases have highlighted the launch of research-grade plasmid DNA preps for nucleic acid therapeutics research, including animal origin-free and transfection-grade options with specific quality attributes and target yields. Other announcements cover expanded collaborations, such as the Trinity Freestyle Fast Hybridization workflow developed with Element Biosciences for the AVITI sequencing platforms.
Investors and researchers can also track earnings-related news, including preliminary revenue updates, quarterly and full-year financial results, and associated conference calls and webcasts. Corporate governance and compensation updates, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4), appear in Twist’s news stream as well.
In addition, Twist publishes news on biosecurity and policy engagement, including participation in a Science paper examining biosecurity screening practices in AI-assisted protein design. Conference presentations at major healthcare and life science events are also regularly announced. For anyone following TWST stock or the evolution of synthetic DNA technologies, this news page provides a centralized view of Twist Bioscience’s public communications and key milestones.
Twist Bioscience (NASDAQ: TWST) said CEO Emily M. Leproust and CFO Adam Laponis will take part in investor fireside chats at three upcoming conferences: TD Cowen on March 3, 2026 (1:50 PM ET), Barclays on March 10, 2026 (3:00 PM ET), and Leerink on March 11, 2026 (8:40 AM ET).
According to the company, each session will be webcast live via the Investor Calendar on the investor relations website, with replays archived for 30 days after each event.
Twist Bioscience (NASDAQ: TWST) entered a licensing agreement to become co-exclusive provider of Invenra's B-Body® bispecific antibody platform, expanding Twist's antibody discovery services to include bispecifics and AI-enabled workflows.
Financial terms include an upfront payment of $5M cash plus $15M in Twist common stock, a $13.8M preferred-stock transaction to acquire ~6% of Invenra, and a 20% royalty payable to Invenra on license revenue. Twist will receive bispecific discovery and license revenues.
Twist Bioscience (NASDAQ: TWST) launched two library preparation kits: the Twist TrueAmp Library Preparation Kit and the Twist PCR-Free WGS Library Preparation Kit on February 10, 2026. Both kits use in-house engineered enzymes (a new polymerase and ligase) to improve coverage, reduce bias, and support low-input or degraded samples for NGS and WGS workflows.
Key technical highlights include compatibility with Twist HT-UDI adapters for up to 3,072 unique indexes, UMI adapters, and support for full-length UDI barcoding for up to 1,536 samples.
Twist Bioscience (NASDAQ: TWST) announced inducement equity awards totaling 114,869 awards—107,742 restricted stock units (RSUs) and up to 7,127 performance stock units (PSUs)—to 52 newly hired individuals under its Amended and Restated Inducement Equity Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
A portion of RSUs vest over 48 months with standard one-year cliff and quarterly vesting; PSUs vest based on performance metrics by the end of fiscal 2027 and may pay out at 50%–150% of target, subject to continued service.
Twist Bioscience (NASDAQ: TWST) announced financial results and business highlights for the fiscal first quarter 2026 ended December 31, 2025. The company will host a conference call and live audio webcast at 8:00 a.m. ET on February 2, 2026 to discuss results.
Investors can access the webcast and register for telephone participation via the Investor Relations Events and Presentations page; the webcast replay will be available for two weeks.
Twist Bioscience (NASDAQ: TWST) announced preliminary, unaudited revenue for the first quarter of fiscal 2026, the quarter ended December 31, 2025. Finalized financial results will be released before market open on February 2, 2026.
The company will host a conference call and live audio webcast for analysts and investors on February 2, 2026 at 8:00 a.m. Eastern Time. Webcast access, registration for telephone participation (which provides a dial-in number and unique PIN), and the replay (available for two weeks) are available through the Investor Relations section of the company website.
Twist Bioscience (NASDAQ: TWST) announced that CEO and co-founder Emily M. Leproust, Ph.D. will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 2:15 pm Pacific Time in San Francisco.
The presentation will be webcast live and available via the company's Investor Calendar on the investor relations website, with a replay archived for 30 days after the live event.
Twist Bioscience (NASDAQ: TWST) launched research-grade Plasmid DNA Preps to support preclinical nucleic acid therapeutics research, including antisense and gene therapies. The offering includes animal origin-free (AOF) and transfection-grade preps, low/endotoxin options, and target yields for prep sizes from 4µg to 10µg. Twist states turnaround for Express Genes starts at four business days. AOF products are available with TSE and BSE certificates to verify quality and meet common preclinical transfer requirements.
Twist Bioscience (NASDAQ: TWST) announced its fiscal 2025 fourth quarter and full year financial results for the period ended September 30, 2025.
The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time on November 14, 2025 to discuss results and business updates. The webcast and replay are available via the Investor Relations Events and Presentations page at investors.twistbioscience.com.
Telephone participants must register on the investor site to receive a dial-in number and unique PIN; callers are advised to dial in 15 minutes early. The webcast replay will be available for two weeks.
Twist Bioscience (NASDAQ: TWST) announced that CEO and co‑founder Emily M. Leproust, Ph.D. and CFO Adam Laponis will participate in a fireside chat at the 7th Annual Wolfe Research Healthcare Conference on Monday, November 17, 2025 at 3:20 PM ET in New York City.
The session will be webcast live and available via the company's Investor Calendar on its investor relations website. A replay will be archived for 30 days after the live event.